TransCode Therapeutics, Inc. (RNAZ) Stock
Healthcare · Biotechnology · Member of Other US Stocks
TransCode Therapeutics, Inc. (RNAZ) closed at USD 1.73 on 2026-10-14, a change of -86.4 % over the past year, with a market capitalization of USD 30.48M.
TransCode Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.73 |
| 2026-10-13 | 1.68 |
| 2026-10-12 | 1.63 |
| 2026-10-09 | 1.86 |
| 2026-10-08 | 1.71 |
| 2026-10-07 | 1.76 |
| 2026-10-06 | 1.78 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
TransCode Therapeutics, Inc. key figures
- Previous close
- USD 1.73 (2026-10-14)
- 1-year change
- -86.4 %
- Market cap
- USD 30.48M
- Enterprise value
- USD 188.8M
- P/E ratio (trailing)
- -0.03
- P/E ratio (forward)
- -3.00
- EPS (trailing)
- -55.61
- EPS (forward)
- -0.60
- PEG ratio
- n/a
- Price to book
- -0.07
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.59
- Employees
- 12
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for TransCode Therapeutics, Inc. and compare it with other stocks.
Analyze RNAZAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell TransCode Therapeutics, Inc. shares.